Suscribirse

Identification of phytochemicals in Qingfei Paidu decoction for the treatment of coronavirus disease 2019 by targeting the virus-host interactome - 15/11/22

Doi : 10.1016/j.biopha.2022.113946 
Yuyun Li a, c, 1, Yan Wu b, 1, Siyan Li e, 1, Yibin Li a, Xin Zhang a, Zeren Shou a, Shuyin Gu a, Chenliang Zhou a, Daohua Xu c, Kangni Zhao a, Suiyi Tan a, Jiayin Qiu d, , Xiaoyan Pan b, , Lin Li a,
a NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China 
b State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan 430071, China 
c Key Laboratory of Traditional Chinese Medicine and New Pharmacy Development, Guangdong Medical University, Dongguan 523808, China 
d School of Pharmaceutical Science, Zhejiang Chinese Medical University, Hangzhou 310053, China 
e School of Basic Medical Sciences, Guangzhou University of Chinese Medicine, Guangzhou 510006, China 

Corresponding authors.

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
Artículo gratuito.

Conéctese para beneficiarse!

Abstract

Qingfei Paidu decoction (QFPDD) has been clinically proven to be effective in the treatment of coronavirus disease 2019 (COVID-19). However, the bioactive components and therapeutic mechanisms remain unclear. This study aimed to explore the effective components and underlying mechanisms of QFPDD in the treatment of COVID-19 by targeting the virus-host interactome and verifying the antiviral activities of its active components in vitro. Key active components and targets were identified by analysing the topological features of a compound-target-pathway-disease regulatory network of QFPDD for the treatment of COVID-19. The antiviral activity of the active components was determined by a live virus infection assay, and possible mechanisms were analysed by pseudotyped virus infection and molecular docking assays. The inhibitory effects of the components tested on the virus-induced release of IL-6, IL-1β and CXCL-10 were detected by ELISA. Three components of QFPDD, oroxylin A, hesperetin and scutellarin, exhibited potent antiviral activities against live SARS-CoV-2 virus and HCoV-OC43 virus with IC50 values ranging from 18.68 to 63.27 μM. Oroxylin A inhibited the entry of SARS-CoV-2 pseudovirus into target cells and inhibited SARS-CoV-2 S protein-mediated cell-cell fusion by binding with the ACE2 receptor. The active components of QFPDD obviously inhibited the IL-6, IL-1β and CXCL-10 release induced by the SARS-CoV-2 S protein. This study supports the clinical application of QFPDD and provides an effective analysis method for the in-depth study of the mechanisms of traditional Chinese medicine (TCM) in the prevention and treatment of COVID-19.

El texto completo de este artículo está disponible en PDF.

Graphical Abstract




ga1

El texto completo de este artículo está disponible en PDF.

Highlights

The active components of QFPDD were identified by targeting the virus-host interactome.
Three serum-absorbed components of QFPDD, oroxylin A, hesperetin and scutellarin, exhibit potent anti-SARS-CoV-2 activity.
Oroxylin A inhibits SARS-CoV-2 entry and S protein-mediated cell-cell fusion.
The active components of QFPDD inhibit the release of SARS-CoV-2 S protein-induced cytokines.

El texto completo de este artículo está disponible en PDF.

Abbreviations : ACE2, CCK-8, COVID-19, CQ, CC50, CXCL-10, DA, DEGs, DMSO, GEO, GO, HE, HR1, HR2, IC50, HCoV-OC43, IL-6, IL-1β, IS, LU, KEGG, NA, NP, OA, OD, PMA, PsV, QFPDD, RT-PCR, RE, RRA, SARS-CoV-2, S, SC, TCM, TCMSP, TE, TMPRSS2, WO, 6-HB

Keywords : COVID-19, Qingfei Paidu Decoction, SARS-CoV-2, Bioinformatics, Systematic pharmacology, Virus-host interactome


Esquema


© 2022  The Authors. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 156

Artículo 113946- décembre 2022 Regresar al número
Artículo precedente Artículo precedente
  • Tenofovir alafenamide alleviates nonalcoholic steatohepatitis in mice by blocking the phosphorylation of AKT in intrahepatic mononuclear phagocytes
  • Pu Reun Roh, Sung Min Kim, Byung-Yoon Kang, Kyoung Do Mun, Jong Geun Park, Min Woo Kang, Wonhee Hur, Ji Won Han, Heechul Nam, Seung Kew Yoon, Pil Soo Sung
| Artículo siguiente Artículo siguiente
  • Efficacy and safety of erythropoietin in a chronic model of Inflammatory Bowel Disease
  • Inês Silva, João Estarreja, Rui Pinto, Vanessa Mateus

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2025 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.